EN | RU
EN | RU

Help Support

Back

Dr. Reddy unveils novel drug 2DGTM for the treatment of COVID-19

Dr. Reddy unveils novel drug 2DGTM for the treatment of COVID-19 Dr. Reddy unveils novel drug 2DGTM for the treatment of COVID-19
Dr. Reddy unveils novel drug 2DGTM for the treatment of COVID-19 Dr. Reddy unveils novel drug 2DGTM for the treatment of COVID-19

What's new?

2-deoxy-D-glucose can be used as an add-on treatment in hospitalized people with moderate to severe COVID-19.

On June 28, 2021, a novel oral drug- 2-deoxy-D-glucose (2-DG) was commercially unveiled by a leading pharmaceutical- Dr. Reddy’s Laboratories. As mentioned, Dr. Reddy will provide this medicine to the leading government and private hospitals all over India. Initially, the organization will make the drug available in hospitals in metros and Tier 1 cities (Delhi, Mumbai, Chennai, Kolkata, Bangalore, Hyderabad, Ahmedabad and Pune), and eventually expand its coverage to the remaining regions.

2-DG will be sold under the brand name 2DGTM with a purity of 99.5%. For the government institutes, a subsidized price has been offered. This drug is a result of a fruitful outcome of Institute of Nuclear Medicine & Allied Sciences (INMAS) and Dr. Reddy's Lab.

It can only be used in hospitalized people suffering from moderate to severe COVID-19 as an add-on therapy to the prevailing standard care as recommended and under the guidance of an experienced doctor. On May 1, 2021, this medicine was given as emergency use authorization for anti-COVID-19 treatment by the Drugs Controller General of India (DCGI). This launch marks 2-DG as yet another milestone in the fight against infectious coronavirus disease (COVID-19).

Source:

Press Release

Article:

Dr. Reddy’s Laboratories Announces Commercial Launch of 2DGTM

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: